Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL

Start Date01 May 2025

Sponsor / Collaborator-

CTRI/2024/12/077774

/ Not yet recruitingNot ApplicableIIT

Memantine as an adjuvant in cognitive symptoms of schizophrenia with chronic course a follow up study - NIL

Start Date01 Jan 2025

Sponsor / Collaborator-

NCT06727773

/ Not yet recruitingPhase 2IIT

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

This randomized, placebo-controlled trial aims to assess the feasibility, acceptability, and preliminary efficacy of memantine and the University of Carolina (UNC)'s Get Real & Heel cancer exercise program (MEM+EX) in addressing cancer-related cognitive impairment (CRCI) and improving cognitive outcomes. Ninety stage I-III breast cancer patients with mild cognitive difficulties during chemotherapy will be randomized into three groups: MEM+EX, memantine, or placebo. The study will evaluate recruitment, retention, adherence, acceptability, cognitive function, BDNF, inflammatory markers, and frailty at multiple time points.

Start Date01 Dec 2024

Sponsor / Collaborator

UNC Lineberger Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Memantine hydrochloride

100 Translational Medicine associated with Memantine hydrochloride

100 Patents (Medical) associated with Memantine hydrochloride

218

Literatures (Medical) associated with Memantine hydrochloride

01 Feb 2025·Pharmaceutical nanotechnology

Optimizing Neuroprotective Nano-structured Lipid Carriers for Transdermal Delivery through Artificial Neural Network

Article

Author: Prajapati, Bhupendra ; Dalwadi, Saloni ; Thakkar, Vaishali

Background::

Dementia associated with Alzheimer’s disease (AD) is a neurological disorder. AD is a progressive neurodegenerative condition that predominantly impacts the elderly population, although it can also manifest in younger people through the impairment of cognitive functions, such as memory, cognition, and behaviour. Donepezil HCl and Memantine HCl are encapsulated in Nanostructured Lipid Carriers (NLCs) to prolong systemic circulation and minimize the systemic side effects.

Objective::

This work explores the use of data mining tools to optimize the formulation of NLCs comprising of Donepezil HCl and Memantine HCl for transdermal drug delivery. Neuroprotective drugs and excipients are utilized for protecting the nervous system against damage or degeneration.

Methods::

The NLCs were formulated using a high-speed homogenization technique followed by ultrasonication. NLCs were optimized using Box Behnken Design (BBD) in Design Expert Software and artificial neural network (ANN) in IBM SPSS statistics. The independent variables included the ratio of solid lipid to liquid lipid, the percentage of surfactant, and the revolutions per minute (RPM) of the high-speed homogenizer.

Results::

The NLCs that were formulated had a mean particle size ranging from 67.0±0.45 to 142.4±0.52 nm. Both drugs have a %EE range over 75%, and Zeta potential was determined to be - 26±0.36 mV. CryoSEM was used to do the structural study. The permeation study showed the prolonged release of the formulation.

Conclusion::

The results indicate that NLCs have the potential to be a carrier for transporting medications to deeper layers of the skin and reaching systemic circulation, making them a suitable formulation for the management of Dementia. Both ANN and BBD techniques are effective tools for systematically developing and optimizing NLC formulation.

02 Oct 2024·DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Application of cocoa butter for formulation of fast melt tablets containing memantine hydrochloride

Article

Author: Phang, Hiu Ching ; Gobal, Ganesan ; Kee, Phei Er ; Goh, Bey Hing ; Vijayaraj Kumar, Palanirajan ; Loke, Ying Hui ; Widodo, Riyanto Teguh ; Liew, Kai Bin

INTRODUCTION:

Fast melt tablets (FMTs) provide a convenient dosage form that rapidly dissolves on the tongue without the need for water. Cocoa butter serves as a suitable matrix system for FMTs formulation, facilitating rapid disintegration at body temperature.

OBJECTIVES:

This study aimed to formulate FMTs using cocoa butter as a base and investigate the effect of various disintegrants and superdisintegrants on their characteristics.

METHODS:

Cocoa butter-based FMTs were prepared via the fusion molding technique. Different disintegrants and superdisintegrants were added at varying concentrations and subjected to characterization. The optimal formulation was selected and incorporated with 10 mg memantine hydrochloride.

RESULTS:

The optimal FMT formulation consisted of 340 mg cocoa butter, 75 mg starch, and 75 mg crospovidone, exhibiting a hardness of 17.12 ± 0.31 N and a disintegration time of 32.67 ± 0.17 s. Furthermore, FMTs demonstrated a faster release profile compared to the commercially available product, Ebixa. SEM micrographs revealed homogenous blending of individual ingredients within the cocoa butter matrix and FT-IR analysis confirmed the chemical stability of memantine hydrochloride in the formulation. The dissolution profile of F17 suggested that the drug in FMTs released faster compared to Ebixia. Memantine hydrochloride achieved 98.07% of drug release in FMTs at 10 min. Moreover, the prepared FMTs exhibited stability for at least 6 months.

CONCLUSION:

The successful development of cocoa butter-based FMTs containing memantine hydrochloride highlights the potential of cocoa butter as viable alternative matrix-forming material for FMTs production. This innovative formulation offers patients a convenient alternative for medication administration.

01 Aug 2024·BIOMEDICINE & PHARMACOTHERAPY

Mitigating radiation-induced brain injury via NLRP3/NLRC4/Caspase-1 pyroptosis pathway: Efficacy of memantine and hydrogen-rich water

Article

Author: Luo, Hao ; Liu, Huan ; Xu, Kai ; Wang, Yuhao ; Lu, Xiaoyu ; Liu, Mengya ; Wang, Yong ; Qin, Xiujun ; Sun, Ge

Radiation-induced brain injury (RIBI) is a significant challenge in radiotherapy for head and neck tumors, impacting patients' quality of life. In exploring potential treatments, this study focuses on memantine hydrochloride and hydrogen-rich water, hypothesized to mitigate RIBI through inhibiting the NLRP3/NLRC4/Caspase-1 pathway. In a controlled study involving 40 Sprague-Dawley rats, divided into five groups including a control and various treatment groups, we assessed the effects of these treatments on RIBI. Post-irradiation, all irradiated groups displayed symptoms like weight loss and salivation, with notable variations among different treatment approaches. Particularly, hydrogen-rich water showed a promising reduction in these symptoms. Histopathological analysis indicated substantial hippocampal damage in the radiation-only group, while the groups receiving memantine and/or hydrogen-rich water exhibited significant mitigation of such damage. Molecular studies, revealed a decrease in oxidative stress markers and an attenuated inflammatory response in the treatment groups. Immunohistochemistry further confirmed these molecular changes, suggesting the effectiveness of these agents. Echoing recent scientific inquiries into the protective roles of specific compounds against radiation-induced damages, our study adds to the growing body of evidence on the potential of memantine and hydrogen-rich water as novel therapeutic strategies for RIBI.

News (Medical) associated with Memantine hydrochloride

16 Dec 2024

·www.alphacognition.com

Alpha Cognition Announces Partial Exercise of Over-Allotment Option

VANCOUVER, British Columbia and Dallas, TX — December 16, 2024 (BUSINESS WIRE) — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of US$5.75 per share for an additional US$2.8 million in gross proceeds. After giving effect to the partial exercise of the over-allotment option, the Company sold an aggregate 9,184,159 common shares for gross proceeds of approximately US$52.8 million, before deducting underwriter discounts and other related expenses. The option closing date was December 16, 2024. The common shares began trading on The Nasdaq Capital Market on November 12, 2024, under the ticker symbol “ACOG”. The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYLTM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering. The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential use of proceeds of the Offering. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future. Contacts For further information: Michael McFadden, CEO Tel: 1-858-344-4375 info@alphacognition.com Titan Partners Contact: Tel: (929) 833-1246 info@titanpartnersgrp.com.

Clinical Study

12 Dec 2024

·www.businesswire.com

Alpha Cognition Announces Voluntary Delisting from CSE

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17, 2024. The Company’s common shares will continue to trade on the Nasdaq under the symbol “ACOG”. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements: This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

Drug Approval

11 Dec 2024

·www.businesswire.com

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Blast caused mTBI is considered to be the signature injury effecting soldiers where brain injury from explosive devices and artillery fire blast exposure is highly prevalent. ACI previously documented extensive functional and neuropathological protection, provided by ALPHA-1062 administration, following a single moderate traumatic brain injury. This second pre-clinical study in a rodent model, supported by the US Department of Defense (DOD), is a collaboration with investigators at the Seattle Institute of Biomedical and Clinical Research (affiliated with both the University of Washington and the Veterans Administration). The study is ongoing, with interim data demonstrating that ALPHA-1062 administration following 3 consecutive days of blast induced mTBI, results in a reduction of TBI associated neuropathology. Key findings demonstrated that, ALPHA-1062 administration reduced levels of neuroinflammation markers and neuropathology that occurs after blast trauma. High dose ALPHA-1062 reduced the levels of myeloid cell activation [CD 68] across multiple brain regions one month after blast. High dose ALPHA-1062 also demonstrated the ability to reduce midbrain astrogliosis [GFAP]. Astrogliosis is a process where brain cells called astrocytes become larger, multiply, and change in response to injury or disease in the brain. “These outcomes indicate a protective effect of ALPHA-1062, and demonstrated a reduction of neuropathology. The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury,” said Denis Kay, ACI’s Chief Scientific Officer. Further analysis of neuropathology and neurobehavioral [functional recovery] data is ongoing with the final study report due Q2/2025. About Alpha Cognition Inc. Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia. An intranasal formulation of ALPHA-1062 has demonstrated potent preservation brain structure and function in a preclinical model of moderate TBI, where enhanced recovery from the brain injury was also seen. The intranasal formulation is currently being evaluated for its ability to provide protection from a military relevant model of repeated mild TBI, in a program sponsored by the US Department of Defense. Neither Canadian Securities Exchange (the “CSE”) or the OTC Markets Group, accepts responsibility for the adequacy or accuracy of this release. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the TBI out-licensing plan and associated financing, the availability of funding pursuant to financings, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

100 Deals associated with Memantine hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D04905	Memantine hydrochloride	N06DX01	DB01043

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	EU	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	IS	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	LI	H. Lundbeck A/S	15 May 2002
Alzheimer Disease	NO	H. Lundbeck A/S	15 May 2002
Dementia	DE	H. Lundbeck A/S	11 Aug 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dementia, Vascular	Phase 3	RU	Merz Pharmaceuticals GmbH	23 Jan 2018
Frontotemporal Dementia	Phase 3	CA	H. Lundbeck A/S	01 Oct 2007
Multiple Sclerosis, Relapsing-Remitting	Phase 3	FR	H. Lundbeck A/S	01 Sep 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	US	Forest Laboratories LLC	01 Jun 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	AR	Forest Laboratories LLC	01 Jun 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	CL	Forest Laboratories LLC	01 Jun 2005
Dementia due to Alzheimer's disease (disorder)	Phase 3	MX	Forest Laboratories LLC	01 Jun 2005
Agitation	Phase 3	US	Forest Laboratories LLC	01 Sep 2004
Cognitive Dysfunction	Phase 3	US	Forest Laboratories, Inc.	01 Apr 2004
Multiple Sclerosis	Phase 3	US	Forest Laboratories, Inc.	01 Apr 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EAN	Not Applicable	Epileptic encephalopathy GRIN2A mutation	88	Memantine 0.5 mg/kg	irnlsjadja(svqqaxrtmr) = slight changes in cognitive skills, overall improvement was noted hzktqejxto (jvrfzljqet ) View more	Positive	28 Jun 2024
NCT04792645 (CTgov)	Phase 2	Trichotillomania \| Skin Diseases	100	Placebo (Placebo)	fototsmtuf(dnvxqmkwbo) = bckehdbwtq bflebjpqol (jxqpifteyl, cwiatavzgb - ftaepfkflu) View more	-	01 Aug 2023
				Memantine (Memantine)	fototsmtuf(dnvxqmkwbo) = zgrxjjuygt bflebjpqol (jxqpifteyl, svveiztjpl - rfnbyxgxem) View more
NCT04698525 (CTgov)	Phase 3	Migraine Disorders	33	Valproate Sodium (Valproate Group)	vypnithrcm(mawfhhtryz) = fieiivbbzn qhxddnxrbz (rqjmzmcopx, xhatdrjypy - fpbwafyzlv) View more	-	17 May 2023
				memantine (Memantine)	vypnithrcm(mawfhhtryz) = fwssxfbbvm qhxddnxrbz (rqjmzmcopx, rhgfdlxikh - toptpsnkww) View more
NCT03860597 (CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	42	Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine)	nqnmpcykwg(fdquglleth) = qfgancvlgq rdokvlqdsa (slwywokhqv, ysxcydozci - hadpjbkmwt) View more	-	21 Dec 2022
				Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo)	nqnmpcykwg(fdquglleth) = hyrjekytyv rdokvlqdsa (slwywokhqv, hzmeycvmut - asaupsgflv) View more
NCT00646204 (CTgov)	Phase 4	Parkinson Disease	40	Memantine-1 (Memantine-1)	jmhehpwkkw(wrgpitaylw) = hrdjeivuct sqhhvwzgio (zifsjkygnf, icsfzhkkjl - ttgxplakja) View more	-	13 Dec 2022
				Placebo (Placebo-2)	jmhehpwkkw(wrgpitaylw) = jczuaisqgd sqhhvwzgio (zifsjkygnf, mupyodjlyp - qcdbwadubf) View more
NCT02118727 (TAME, CTgov)	Phase 2	Frontotemporal Dementia \| Amyotrophic Lateral Sclerosis	89	Memantine (Memantine)	fpetukvkka(qcotyypois) = vmxipmnvtt lrnuyjaboy (boqoerqxzc, kzrscahbsn - aimsvelnyb) View more	-	29 Nov 2022
				Placebo (for Memantine) (Placebo)	fpetukvkka(qcotyypois) = eqahsvujfo lrnuyjaboy (boqoerqxzc, usdltcmvsm - wuwvjfstpk) View more
SFN2022	Not Applicable	Autism Spectrum Disorder	-	Memantine	esffedzlwm(pgaxcgxuue) = radfapswpx dzyzpbbfrl (hfhzukuwvs )	-	16 Nov 2022
NCT03779672 (Pubmed \| Brain)	Phase 4	Epileptic encephalopathy	30	Memantine	xsyrkxyzfh(mqkhcdhcxx) = gwcbfdkvig aqenfsahop (vowwhlpxsq )	Positive	18 Oct 2022
				Placebo	xsyrkxyzfh(mqkhcdhcxx) = qdzsijrxmm aqenfsahop (vowwhlpxsq )
NCT04033419 (ASCO2022) Manual	Phase 2	Early Stage Breast Carcinoma	56	memantine	nrbkytoynw(tvgtzqtciq) = gqtatuopkf apjrebxnrl (ecxnsdxpdm ) View more	Positive	02 Jun 2022
NCT02304302 (CTgov)	Phase 2	Down Syndrome	160	Placebo (Placebo)	ktlbhisohm(hiijucronz) = uhrwrfktcq umqtscwvmn (cnlhnfazmj, sypdgrrexs - twrbegxdak) View more	-	05 Apr 2022
				Memantine (Memantine)	ktlbhisohm(hiijucronz) = nuoooufyoa umqtscwvmn (cnlhnfazmj, hmafxmymnw - hwhtttbpsh) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Memantine hydrochloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation